<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04241198</url>
  </required_header>
  <id_info>
    <org_study_id>Home Imaging using NOTAL-OCT</org_study_id>
    <nct_id>NCT04241198</nct_id>
  </id_info>
  <brief_title>Home Retinal Imaging Using NOTAL-OCT V3.0</brief_title>
  <official_title>Home Retinal Imaging Using NOTAL-OCT V3.0</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Notal Vision Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Notal Vision Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will include up to 30 AMD patients, recruited by two medical centers, Tel-Aviv&#xD;
      medical center and Assuta Hashalom medical center. At the screening visit, the patients will&#xD;
      be imaged in their tested, eligible eye(s), using a commercial Zeiss Cirrus or Heidelberg&#xD;
      Spectralis OCT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening visit:&#xD;
&#xD;
      For patients eligible to participate in the study, the following procedure will be done in&#xD;
      the &quot;screening visit&quot; at the clinic:&#xD;
&#xD;
        1. Patient will sign the IC (Informed Consent) form&#xD;
&#xD;
        2. The following demographic and clinical data will be collected and registered in the CRF:&#xD;
&#xD;
             1. Patient's DOB and gender.&#xD;
&#xD;
             2. Patient's diagnosis in study eye(s), based on patient's medical record, including&#xD;
                media opacity (e.g. cataract or corneal opacity, if exists).&#xD;
&#xD;
             3. Bio-microscopy testing.&#xD;
&#xD;
             4. Refraction correction by an optometrist.&#xD;
&#xD;
             5. Habitual Snellen visual acuity&#xD;
&#xD;
             6. Commercial OCT scanning using Zeiss Cirrus or Heidelberg Spectralis.&#xD;
&#xD;
      OCT scanning pattern:&#xD;
&#xD;
        -  Macular cube of at least 6X6mm (20 degrees)&#xD;
&#xD;
        -  At least 40 B-scans per cube&#xD;
&#xD;
      Setup and tutorial home visit:&#xD;
&#xD;
      The device will be delivered to the patient's home with a setup guide attached to the&#xD;
      package. The patient will read the setup guide instructions, unpack the device, place it on a&#xD;
      table and connect it to a power supply. Upon first usage a tutorial clip, explaining how to&#xD;
      operate the device and self-image the eyes, will be automatically displayed on the device's&#xD;
      external screen. Following the tutorial patients will be instructed to scan their study&#xD;
      eye(s). A remote support service, provided by the sponsor, will be available as needed. Its&#xD;
      phone number will be given to the patient and will be attached to the device's base.&#xD;
&#xD;
      Daily home testing:&#xD;
&#xD;
      For each eligible eye, the following procedure will be done in the &quot;Daily testing&quot; at the&#xD;
      patients' homes:&#xD;
&#xD;
        1. The patients will be requested to self-scan their study eye(s) daily, using the&#xD;
           NOTAL-OCT V3.0..&#xD;
&#xD;
        2. The patient will be able call the sponsor's remote support service, during working&#xD;
           hours, for assistance in case of questions or problems regarding the operation the&#xD;
           NOTAL-OCT V3.0 device.&#xD;
&#xD;
      Exit visit:&#xD;
&#xD;
      For each eligible eye, the following procedure will be done in the &quot;Exit visit&quot; at the&#xD;
      clinic:&#xD;
&#xD;
        1. Bio-microscopy testing.&#xD;
&#xD;
        2. Refraction correction by an optometrist.&#xD;
&#xD;
        3. Habitual Snellen visual acuity&#xD;
&#xD;
        4. Commercial OCT scanning using Zeiss Cirrus or Heidelberg Spectralis.&#xD;
&#xD;
      OCT scanning pattern:&#xD;
&#xD;
        -  Macular cube of at least 6X6mm (20 degrees)&#xD;
&#xD;
        -  At least 40 B-scans per cube NOTAL-OCT V3.0 Scanning.&#xD;
&#xD;
           6.Patient's experience questionnaire&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To describe the dynamics of retinal fluid</measure>
    <time_frame>30 days</time_frame>
    <description>To describe the dynamics of retinal fluid in eyes undergoing anti-VEGF therapy as manifested in self-operated OCT in daily home testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate patient experience when self-operating the Notal-OCT V3.0.</measure>
    <time_frame>30 days</time_frame>
    <description>by a patient experience questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E. To evaluate the level of agreement between OCT images captured by Notal-OCT V3.0 and a commercial OCT</measure>
    <time_frame>30 days</time_frame>
    <description>E. To evaluate the level of agreement between OCT images captured by Notal-OCT V3.0 and a commercial OCT, for the presence of fluid, in the central 10 degrees of the macula, at screening and exit visits.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>A. AMD Patients, Where at Least One Eye is With Active CNV, Presenting Retinal Fluid at the Enrolment Visit, Undergoing Active Anti-VEGF Treatment</condition>
  <eligibility>
    <study_pop>
      <textblock>
        AMD patients, where at least one eye is with active CNV, presenting retinal fluid at the&#xD;
        enrolment visit, undergoing active anti-VEGF treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability and willingness to give informed consent (IC)&#xD;
&#xD;
          2. 18 years of age or older at the time of IC&#xD;
&#xD;
          3. Tested eye(s) diagnosed with AMD&#xD;
&#xD;
          4. Visual acuity of 20/400 Snellen (6/120) or better in the study eye&#xD;
&#xD;
          5. At least one eye is with active CNV, presenting retinal fluid at the enrolment visit,&#xD;
             undergoing active anti-VEGF treatment&#xD;
&#xD;
          6. Ability to undergo OCT testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        NA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>michaela Glodstein, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muki Rapp</last_name>
    <phone>+792526118884</phone>
    <phone_ext>+792526118884</phone_ext>
    <email>rapp@notalvision.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>TLV Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

